HLB combination shows consistent liver-cancer efficacy across patient age groups
AI Summary- Elevar Therapeutics will present CARES-310’s age-based analysis at ILCA 2026.
- 21.5 months was median overall survival under 50, versus 15.2 months with sorafenib.
- FDA issued a July complete response letter over cGMP issues at a production facility.